Clinical study on ixazomib-based chemotherapy regimens in treatment of relapsed/refractory multiple myeloma
10.3760/cma.j.cn115356-20200930-00239
- VernacularTitle:伊沙佐米为基础的化疗方案治疗复发难治多发性骨髓瘤临床研究
- Author:
Bin FU
1
;
Lihua GU
;
Ping LIU
;
Fujin SUN
;
Qianhui ZHANG
;
Jianmin GUAN
Author Information
1. 山东省菏泽市立医院血液科 274000
- Keywords:
Multiple myeloma;
Recurrence;
Antineoplastic combined chemotherapy protocols;
Treatment outcome;
Ixazomib
- From:
Journal of Leukemia & Lymphoma
2021;30(6):340-343
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and related adverse reactions of ixazomib-based chemotherapy regimens in the treatment of relapsed/refractory multiple myeloma (RRMM).Methods:Twenty-one patients with RRMM who received ≥2 courses of ixazomib-based chemotherapy regimens in Heze Municipal Hospital and Zoucheng People's Hospital of Shandong Province from October 2018 to February 2020 were collected. Among them, 15 patients had previously received the bortezomib-based regimens, 10 patients had received the lenalidomide-based regimens, and 6 patients had received the treatment regimens containing the above two drugs. The patients were treated by a two-drug or three-drug regimen: 4 mg ixazomib was taken orally on day 1, 8 and 15 in combination with other drugs (dexamethasone, cyclophosphamide or lenalidomide). The therapeutic efficacy and safety were evaluated after the 2nd and the 4th treatment cycles.Results:The overall response rate (ORR) of 21 patients with RRMM after 2 treatment cycles was 38.09% (8/21), including 6 cases of partial remission (PR) and 2 cases of very good partial remission (VGPR). After 4 cycles, ORR was 57.14% (12/21), including 7 cases of PR, 4 cases of VGPR, and 1 case of complete remission (CR). The incidence of grade 3-4 adverse reactions of the ixazomib-based chemotherapy regimens was 23.81% (5/21). Hematological adverse reactions included neutropenia, thrombocytopenia and anemia, and other common adverse reactions included the digestive tract reactions, fatigue, hypokalemia, etc., and the peripheral nerve adverse reactions were all grade 2 or below grade 2.Conclusion:The ixazomib-based chemotherapy regimens are effective and safe in treating RRMM.
